Following up to the original article - Globus continues to eat orthopedics with fantastic financial numbers including 25% revenue growth Y/Y.
Look at this performance by the numbers below.
Globus Medical (NYSE: GMED) delivered strong year-over-year growth in 2025, with acceleration in Q4, driven by solid base-business performance, the Nevro acquisition (which contributed ~$99.7 million in Q4 sales), and ongoing benefits from the earlier NuVasive integration. The company highlighted double-digit sales/earnings growth, margin expansion, and operating leverage. Below is a clear YoY summary dire...
